Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus

Weiye Ou

doi:10.47297/wspbtsWSP2755-952106.20260501

PDF
Export
Share
Collection
Album

Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus

Volume 5, Issue 1

Views: 0 Downloads: 0

Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus
Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus
Zhejiang MEBOLO Biotechnology CO.,Ltd, Jinhua, Zhejiang, 321000, China
Vol. 5, Issue 1, Pages: 27-32(2026)
Online First：12 August 2026，

Published：30 March 2026
DOI：10.47297/wspbtsWSP2755-952106.20260501
Accepted：

Scan QR Code

Ou Weiye.Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus[J].Biomedical Testing & Sensing,2026,05(01):27-32.
DOI：

Ou Weiye.Population Infection Risk and Whole-process Health Management Strategy of Vaccines Regarding Pigs as Mixers of Influenza A Virus[J].Biomedical Testing & Sensing,2026,05(01):27-32. DOI： 10.47297/wspbtsWSP2755-952106.20260501.

摘要

Abstract

Pigs simultaneously express both α-2

3 and α-2

6 sialic acid receptors in their respiratory tracts

which enables them to be co-infected by avian-origin

human-origin and swine-origin influenza A viruses and facilitate viral genetic reassortment. Therefore

pigs are recognized as the mixing vessel of influenza viruses and play a crucial role in the origin and cross-species transmission of novel pandemic influenza strains. This paper systematically elaborates the three internal logical mechanisms of pigs serving as the mixing vessel of influenza A viruses. It further identifies typical population infection risks from four dimensions: occupational exposure

pathogenicity of recombinant strains

community transmission and potential pandemic threats. On this basis

this paper proposes whole-process health management strategies covering the research and development as well as production of vaccines

cold chain storage and transportation

on-site vaccination

and vaccine waste disposal and subsequent treatment. The objective is to improve the quality of infection prevention and control through standardized and effective health management.

关键词

Keywords

references

Han, D., Guo, X. J., Zhai, C. C., Deng, Y., Huang, B. Y., Hu, Y. C., Ren, J., Wang, W., Guo, J. J., Lu, F. N., Wang, W. L., Shen, X. L., Lu, Z. Z., Wang, J., & Tan, W. J. (2022). Bivalent recombinant adenovirus vector vaccine against SARS-CoV-2 Beta variant and influenza A H3N2 induces immune protection in mice. Virologica Sinica , 38 (5), 1025–1034.

Ning, S., Ding, Y. H., Rong, H., Chi, Y., Ge, Y. Y., & Cui, L. B. (2025). Research path of vaccines and drugs for X disease: Enlightenment from COVID-19 and influenza A. Jiangsu Journal of Preventive Medicine , 36 (4), 408–414.

Shao, Y. Q., Dong, W. B., Xia, Y. P., Zhang, C., & Liu, Y. (2025). Retrospective cohort study on protective effect of influenza vaccination against influenza A among population aged 3–17 years in Fenghua District, Ningbo, 2022–2023. Shanghai Journal of Preventive Medicine , 37 (8), 654–658.

Shen, H. Q., Yu, K. Y., Chen, Y. Y., Ji, P., & Wang, Y. (2023). Preparation and boosting immunization strategy of mRNA vaccine based on hemagglutinin of influenza A H1N1 subtype. Journal of Shanghai Jiao Tong University (Medical Science) , 43 (11), 1374–1383.

Wang, T. Q., Han, R. W., Cheng, X. T., Bing, J. L., Li, J., Sun, S. C., Guo, J. J., Zhai, C. C., Guo, X. Y., Wang, D. H., Wang, W. L., Zhou, J. F., Deng, Y., & Tan, W. J. (2024). Immune response and protection induced by hemagglutinin stem subunit vaccine of influenza A H1N1 combined with different adjuvants in mice. Virologica Sinica , 40 (1), 1–12.

Zhou, Y. F., Yang, Z. H., Gao, J., Yuan, L., & Lei, H. (2025). Immunogenicity and protective efficacy of mRNA vaccine against influenza A (H1N1) in mice. Chinese Pharmaceutical Journal , 60 (10), 1013–1018.